Abstract
To date, no effective treatment is available for advanced cancers, which remain a major cause of morbidity and mortality. Clearly, there is urgent need to unravel novel biomarkers for early detection. Proteomic approaches for the identification of novel biomarkers for cancer diagnosis and staging have traditionally relied on the identification of differentially expressed proteins between tumour cells and their normal counterparts based on the patterns of protein expression observed by two-dimensional gel electrophoresis (2DE-PAGE). Recent advances in mass spectrometry and bioinformatics and statistical algorithms necessary to interpret mass spectrometric data have revolutionized the approach to defining new tumour markers. Proteomics studies have generated numerous datasets of potential prognostic, diagnostic and therapeutic significance in human cancer. In this review we will discuss the available proteomic technologies their limitations and highlight the key areas of research required for understanding the aetiology of cancer and how they have been used to discover cancer biomarkers.
Keywords: Biomarkers, MALDI-TOF, mass spectrometry, 2DE gels, cancer
Current Cancer Therapy Reviews
Title: Application of Proteomics to the Discovery of Cancer Biomarkers
Volume: 4 Issue: 2
Author(s): Murrium Ahmad and Balwir Matharoo-Ball
Affiliation:
Keywords: Biomarkers, MALDI-TOF, mass spectrometry, 2DE gels, cancer
Abstract: To date, no effective treatment is available for advanced cancers, which remain a major cause of morbidity and mortality. Clearly, there is urgent need to unravel novel biomarkers for early detection. Proteomic approaches for the identification of novel biomarkers for cancer diagnosis and staging have traditionally relied on the identification of differentially expressed proteins between tumour cells and their normal counterparts based on the patterns of protein expression observed by two-dimensional gel electrophoresis (2DE-PAGE). Recent advances in mass spectrometry and bioinformatics and statistical algorithms necessary to interpret mass spectrometric data have revolutionized the approach to defining new tumour markers. Proteomics studies have generated numerous datasets of potential prognostic, diagnostic and therapeutic significance in human cancer. In this review we will discuss the available proteomic technologies their limitations and highlight the key areas of research required for understanding the aetiology of cancer and how they have been used to discover cancer biomarkers.
Export Options
About this article
Cite this article as:
Ahmad Murrium and Matharoo-Ball Balwir, Application of Proteomics to the Discovery of Cancer Biomarkers, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310089
DOI https://dx.doi.org/10.2174/157339408784310089 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation
Current Pharmacogenomics and Personalized Medicine Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Current Medicinal Chemistry Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Cancer Stem Cells Equipped with Powerful Hedgehog Signaling and Better Epigenetic Memory: Avenues to Look for Cancer Therapeutics
Current Cancer Drug Targets Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design Principles of an Adenovirus-Based Assay for Candidate Compounds with Broad Spectrum of Anti-Neoplastic Activities
Letters in Drug Design & Discovery Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry The Alcoholic Bark Extract of <i>Terminalia Arjuna</i> Exhibits Cytotoxic and Cytostatic Activity on Jurkat Leukemia Cells
Venoms and Toxins Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued)